Literature DB >> 1186774

Lymphocytotoxic antibody in inflammatory bowel disease. A family study.

S J Korsmeyer, R C Williams, I D Wilson, R G Strickland.   

Abstract

The prevalence of lymphocytotoxic antibody in inflammatory bowel disease is 40 per cent. Twenty-seven of 90 relatives of 23 probands with the disease (30 per cent) demonstrated lymphocytotoxic antibody, as contrasted with only three of 69 control family members (4 per cent) (P less than 0.0001). Decreased lymphocytotoxicity against lymphocytes from patients with inflammatory bowel disease as compared to normal donor lymphocytes previously demonstrated in the serum of probands was also observed in the serums from family members of the probands. Nineteen of the 48 household contacts of probands (40 per cent) were positive for antibody, whereas eight of 42 nonhousehold contacts (19 per cent) demonstrated it (P less than 0.05). Eight of 16 spouses (50 per cent) of probands showed antibody. The increased prevalence of lymphocytotoxic antibody in family members of probands and its occurrence mainly in household contacts (consanguineous and non-consanguineous) may indicate the exposure of probands and their family members to a common environmental agent.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1186774     DOI: 10.1056/NEJM197511272932203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

Review 1.  Neutrophil autoantibodies as disease markers for ulcerative colitis.

Authors:  F Shanahan; C Landers; R Duerr; S R Targan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Ferritin in Crohn's disease tissue: detection by electron microscopy.

Authors:  P J Whorwell; R C Baldwin; R Wright
Journal:  Gut       Date:  1976-09       Impact factor: 23.059

3.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

4.  Immune status in healthy relatives of patients with familial Crohn's disease.

Authors:  A Van Gossum; E Dupont; L Schandene; M Cremer; J Wybran
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

Review 5.  Hodgkin's disease and anergy.

Authors:  T A Shiftan; J Mendelsohn
Journal:  Blut       Date:  1979-01-22

6.  Loss of suppressor T-cells in active inflammatory bowel disease.

Authors:  N J Godin; D B Sachar; R Winchester; C Simon; H D Janowitz
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

7.  Significance of anergy to dinitrochlorobenzene (DNCB) in inflammatory bowel disease: family and postoperative studies.

Authors:  S Meyers; D B Sachar; R N Taub; H D Janowitz
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

8.  Lymphocytotoxic antibodies in patients with inflammatory bowel disease and their spouses--evidence for a transmissible agent.

Authors:  R G Strickland; W C Miller; N A Volpicelli; R F Gaeke; I D Wilson; J B Kirsner; R C Williams
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

Review 9.  Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls.

Authors:  Natalie E Duran; Daniel W Hommes
Journal:  Therap Adv Gastroenterol       Date:  2016-04-25       Impact factor: 4.409

10.  Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment.

Authors:  M Oudkerk Pool; P M Ellerbroek; B U Ridwan; R Goldschmeding; B M von Blomberg; A S Peña; K M Dolman; H Bril; W Dekker; J J Nauta
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.